Breast Cancer Features Archive

General Oncology Effect of BRCA Mutations on Ovarian Reserve After Chemotherapy

Effect of BRCA Mutations on Ovarian Reserve After Chemotherapy

Women with BRCA 1/2 mutations have lower ovarian reserve and experience greater ovarian reserve loss after chemotherapy compared with those who are BRCA wild-type.

Breast Cancer Whole-Exome Sequencing Assessment of Intratumor Genetic Heterogeneity Is Noisy, Error-Prone

Whole-Exome Sequencing Assessment of Intratumor Genetic Heterogeneity Is Noisy, Error-Prone

Whole-exome sequencing at standard depths of coverage is prone to technical noise and false positives, researchers reported.

General Oncology Gene-Delivery Method Generates Immune Checkpoint Antibodies In Vivo

Gene-Delivery Method Generates Immune Checkpoint Antibodies In Vivo

In mice, DNA-encoded plasmids generated sufficient in vivo expression of immune checkpoint antibody CTLA-4; DMabs may one day rival traditional mAbs.

General Oncology Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Preexisting Immunity to CRISPR-Cas9: A Problem for Gene Editing in Cancer?

Evidence is building to show that most people have preexisting immunity to CRISPR-based therapies. In cancer, however, it's unclear how much that matters.

General Oncology Cancer Recurrence: Tackling a Valid Survivor Fear

Cancer Recurrence: Tackling a Valid Survivor Fear

Researchers are learning that roughly half of survivors live with a moderate to high degree of fear of recurrence, and teaching techniques to better cope with uncertainty is one way to help.

Breast Cancer Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?

Lower-Dose, Shorter-Duration Chemotherapy Regimens: Is This a Trend?

Lower doses and shorter treatment regimens have the potential to reduce both physical and financial toxicity for patients.

General Oncology Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Breast Cancer Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up

Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up

High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.

Breast Cancer Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype

Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype

Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.

General Oncology Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

General Oncology The Patient Behind the EHR: Oncologists Only See Half the Picture

The Patient Behind the EHR: Oncologists Only See Half the Picture

Dr Vorobiof discusses the important patient factors that can be missed via standard data collection methods for those with cancer.

Breast Cancer Second Opinion from Cancer Center Yielded Valuable Information for Breast Cancer Management

Second Opinion from Cancer Center Yielded Valuable Information for Breast Cancer Management

A change in diagnosis was often the result of review by a multidisciplinary tumor board at the NCI-designated cancer center.

Breast Cancer The Immune Landscape in Metastatic Breast Cancer Is "More Inert"

The Immune Landscape in Metastatic Breast Cancer Is "More Inert"

Researchers compared the immune microenvironments of primary tumors with those at sites of metastases.

General Oncology Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Who Determines What 'Value' Looks Like in Value-Based Cancer Care?

Evaluation of patient-reported outcomes (PROs) is an important component of measuring quality in cancer care.

General Oncology Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD

Dr Ross described how genomic reports may need to be updated to account for new insights into a variant's role in cancer.

General Oncology Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection

A ctDNA testing method has the capability to predict cancer recurrence, which could help guide therapy selections and uncover new drug development opportunities.

General Oncology Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?

In clinical practice, most physicians and nurse practitioners do not feel comfortable enough with their medical knowledge of cannabis to offer it to patients.

General Oncology Fall of Star Cancer Researcher Brings Broader Picture Into View

Fall of Star Cancer Researcher Brings Broader Picture Into View

Dr José Baselga failed to disclose his financial ties to pharmaceutical companies in top-tier journals, causing many to question whether conflicts of interest are being properly reported.

Breast Cancer Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

Talazoparib Found to Confer a Survival Advantage in BRCA1/2-Positive Breast Cancer

Oral treatment with talazoparib improved progression-free survival and some quality of life measures compared with standard chemotherapy.

Breast Cancer BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors

Double mutants may predict resistance to PARP inhibitors and could also indicate sensitivity to alternative treatments.

General Oncology Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

Oncology Community Expresses Concern About Medicare Advantage Step-Therapy Policy

More than 90 medical societies have called on the US government to reverse a policy allowing step therapy under Medicare Advantage.

Breast Cancer Identifying Gene Variants Involved in Radiotherapy Toxicity Risk: A Q&A With Benjamin Smith, MD

Identifying Gene Variants Involved in Radiotherapy Toxicity Risk: A Q&A With Benjamin Smith, MD

Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.

General Oncology FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

FDA Guidance: Expansion Cohort Trials Expected to Modernize Oncology Trials

There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.

Breast Cancer High BMI Linked With Lower Breast Cancer Risk in Premenopausal Women

High BMI Linked With Lower Breast Cancer Risk in Premenopausal Women

Having a high body mass index reduces the risk for developing breast cancer before menopause, but more research is needed to understand the biological mechanism.

General Oncology Bispecific Antibodies in Cancer

Bispecific Antibodies in Cancer

Interest in these bioengineered antibodies has been rekindled by the striking success seen in the treatment of some cancers with immunotherapies.

General Oncology Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Cognitive Functioning Affects the Ability of Patients With Advanced Cancer to Give Informed Consent

Approximately half of patients with advanced cancer who are enrolled in phase 1 clinical trials do not know the ultimate goal of the study.

General Oncology Triclosan and Cancer Risk: Is There a Link?

Triclosan and Cancer Risk: Is There a Link?

Some studies suggest triclosan could have oncogenic properties, but more research is needed to confirm a causal link.

General Oncology Is Genomic Medicine Failing Minority Patients?

Is Genomic Medicine Failing Minority Patients?

Racial minorities are poorly represented in genomic research databases, raising important questions about whether or not all patients will benefit equally from advances in precision oncology.

General Oncology ARID1A Mutations Might Predict Tumor Response to Immunotherapy

ARID1A Mutations Might Predict Tumor Response to Immunotherapy

New findings bolster the case for the predictive utility of ARID1A mutations.

General Oncology Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

Liquid Biopsies and Cancer Detection: New Test Assesses Levels of Circulating Proteins for Early-Stage Diagnosis

A new test has been shown to be capable of identifying eight different cancers by assessing levels of circulating proteins along with mutations in cell-free DNA.

General Oncology Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Understanding Telomerase: Higher Quality Images Give Insight Into Developing New Agents for Inhibition

Telomerase plays a crucial role in tumor proliferation, and a better understanding of its structure will pave the way for new drug development.

General Oncology Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Efficacy and Hyperemesis Syndrome Associated With Cannabinoid Use in Cancers ― In the Clinic

Many clinical trials and systematic reviews note that the use of cannabinoids also comes with adverse events, including a clinical entity that has been gaining evidence in the literature over the last decade called cannabinoid hyperemesis syndrome.

Breast Cancer Six-Month Trastuzumab Sufficient for HER2-Positive Early-Stage Breast Cancer

Six-Month Trastuzumab Sufficient for HER2-Positive Early-Stage Breast Cancer

Assignment to 6 months of adjuvant trastuzumab was non-inferior to 12 months trastuzumab in women with HER2-positive, early breast cancer.

Prostate Cancer Can Oncolytic Viruses Improve Immunotherapies?

Can Oncolytic Viruses Improve Immunotherapies?

Emerging evidence shows that injecting tumors directly into one tumor can trigger systemic antitumor immunity and immune attacks on untreated tumors elsewhere in the body.

General Oncology Clonally Transmissible Cancers in Nature

Clonally Transmissible Cancers in Nature

While a recent discovery of a series of communicable cancers has raised concerns, there has been no sign of readily transmittable cancer in people that could spread through a population the way the ones found in other species do.

Breast Cancer New Methodology May Advance Precision Medicine

New Methodology May Advance Precision Medicine

A new technology is being developed by Caris Life Sciences to help improve the understanding of aberrant modulations that drive cancer.

General Oncology The Hunt for Effective Anticancer Vaccines

The Hunt for Effective Anticancer Vaccines

Researchers are hotly pursuing 2 distinct biological paths that show remarkable promise in the hunt for an effective anticancer vaccine.

Breast Cancer Breast Cancer: Determining the Best Diet for Disease Prevention

Breast Cancer: Determining the Best Diet for Disease Prevention

Higher ERDP scores were significantly associated with developing breast cancer.

Breast Cancer Widening the Use of Preventive Therapies Against Breast Cancer

Widening the Use of Preventive Therapies Against Breast Cancer

Preventive treatments are strongly recommended in women with AH and LCIS.

General Oncology HIV-Associated Cancers: A Paradigm Shift?

HIV-Associated Cancers: A Paradigm Shift?

Many HIV-associated cancers develop with the help of oncoviruses — some of which are sexually transmitted.

Breast Cancer Identifying the Optimal Breast Cancer Screening Interval

Identifying the Optimal Breast Cancer Screening Interval

It is unclear whether breast cancer screening — and specifically mammography — reduces the likelihood of being diagnosed with advanced-stage disease.

General Oncology Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Anticancer Immunotherapy to Circumvent Tumor Resistance to Immune Checkpoint Inhibitors

Most tumors do not respond, or evolve resistance, to immune checkpoint inhibition. Now, researchers at Johns Hopkins have engineered a new class of cancer immunotherapy agents designed to short-circuit key mechanisms of tumors' disruption and evasion of immune system attack.

General Oncology Phase 1 Trials: Therapy, Not Just Science

Phase 1 Trials: Therapy, Not Just Science

Phase 1 trials should be considered therapeutic options for some patients.

Side Effect Management Immunotherapy and the Risk of Myocarditis

Immunotherapy and the Risk of Myocarditis

The risk should not discourage patients with cancer from taking these potentially life-extending therapies.

General Oncology Clostridium Difficile Infection in Patients With Cancer — In the Clinic

Clostridium Difficile Infection in Patients With Cancer — In the Clinic

While CDI is becoming more common in all hospitalized patients, patients with cancer appear to be at an elevated risk.

General Oncology Can A Consortium of Hospitals Help To Reduce Drug Prices?

Can A Consortium of Hospitals Help To Reduce Drug Prices?

To help curb drug prices, a consortium of hospital groups recently announced plans to form their own nonprofit drug company.

General Oncology Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib: Promising for All TRK-Positive Tumors

Larotrectinib may have durable antitumor activity in patients with TRK fusion-positive cancers, regardless of tumor type.

Brain Cancer Interest in Oncolytic Viruses Continues To Grow

Interest in Oncolytic Viruses Continues To Grow

A variety of viruses are being researched in cancers including melanoma, brain tumors, breast cancers, and others.

General Oncology Diagnosing Medicine's Intractable Gender Pay Gap

Diagnosing Medicine's Intractable Gender Pay Gap

The #MeToo movement has inspired many women to relate stories of harassment, and medicine is no exception.

Side Effect Management Managing Adverse Events in the Era of Immunotherapy

Managing Adverse Events in the Era of Immunotherapy

The novelty of immunotherapies means that physicians and patients lack extensive experience dealing with them.

General Oncology Healthful Lifestyles and Cancer: Much More Than A Single Behavior

Healthful Lifestyles and Cancer: Much More Than A Single Behavior

A recent study is the first to demonstrate the cumulative effect of a large number of lifestyle behaviors.

General Oncology Cancer Immunosurveillance Comes of Age

Cancer Immunosurveillance Comes of Age

As oncologists learn to target the immune response to "self and non-self," a delicate therapy balance will eventually be achieved with predictable outcomes, benefits, and toxicity in the fight against cancer.

General Oncology AI: Inroads Into Clinical Oncology

AI: Inroads Into Clinical Oncology

Novel algorithms may be able to diagnose and plan cancer treatments more effectively than humans, but it's unclear if and when artificial intelligence will be integrated into clinical practice.

Breast Cancer Should Adjuvant Pertuzumab Be Used for Patients With HER2-Positive Breast Cancer?

Should Adjuvant Pertuzumab Be Used for Patients With HER2-Positive Breast Cancer?

While APHINITY showed a small improvement with adjuvant pertuzumab, it is unclear whether the benefits are worth the cost, time, and toxicity associated with the drug.

Breast Cancer Do Oral Contraceptives Actually Increase Breast Cancer Risk?

Do Oral Contraceptives Actually Increase Breast Cancer Risk?

There is no evidence that women at high risk of breast cancer, such as those who harbor BRCA1 or BRCA2 mutations, should avoid hormonal contraception.

General Oncology Does Immune Checkpoint Inhibition Have A Dark Side?

Does Immune Checkpoint Inhibition Have A Dark Side?

Careful research is needed to ensure that immunotherapies activating T cells do not inadvertently fuel progression of T cell malignancies.

General Oncology Cannabis for Cancer: An Uncertain Future

Cannabis for Cancer: An Uncertain Future

While some researchers are attempting to determine whether cannabis has any anti-tumor activity, the FDA recommends that patients do not listen to websites touting the benefits of cannabidiol.

Breast Cancer Locoregional Breast Cancer Recurrence: Advances Are Outpacing Strategies

Locoregional Breast Cancer Recurrence: Advances Are Outpacing Strategies

Treatment advances over recent years render much of the previously used evidence outdated.

General Oncology Can Understanding the Gut Microbiome Improve Clinical Oncology?

Can Understanding the Gut Microbiome Improve Clinical Oncology?

Researchers hope to define what constitutes a functionally healthy microbiome not just in cancer, but across the health spectrum.

General Oncology Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

Cancer Drug Addiction: Prospects for Integrated Therapeutic Management

The drug addiction strategy must be broadened to account for non-addicted cells, sensitive or resistant, that remain after therapy. Much as selection should favor the development of drug resistant tumor cell lineages, it should also favor lineages that are resistant to addiction.

General Oncology Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

Can Inhibiting Ubiquitin Target Undruggable Tumor Proteins?

A class of DUBs known as the ubiquitin-specific-processing proteases are involved in regulating the p53 signaling pathway and have been implicated in tumorigenesis and radiotherapy resistance.

Breast Cancer Metastatic Breast Cancer: What To Look For

Metastatic Breast Cancer: What To Look For

As breast cancer can be asymptomatic or have a series of different symptoms and physical exam findings, standard procedure is hard to define.

General Oncology The Warburg Effect: Can Cancer Be Starved of Sugar?

The Warburg Effect: Can Cancer Be Starved of Sugar?

A recent study into the relationship between glucose and cancer cell proliferation may be helping to identify a therapeutic route to starve tumors without killing normal cells.

Breast Cancer Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?

Can Targeting Inflammatory Microenvironments Improve Cancer Therapy Effectiveness?

Targeting tumor and extracellular LPA could help deny tumors their inflammatory habitat and improve the efficacy of radiotherapy, chemotherapy, and possibly immunotherapies.

Breast Cancer Nano-pulse Stimulation Shows Early Preclinical Promise

Nano-pulse Stimulation Shows Early Preclinical Promise

NPS with electrodes is under investigation as a potential new ablative — and possibly immunotherapeutic — cancer treatment modality.

General Oncology Genetic Predisposition to Cancer: Where Are We Now?

Genetic Predisposition to Cancer: Where Are We Now?

In part 2 of a 2-part series, Bryant Furlow discusses advances in genome sequencing technologies and the resulting insights into associations between inherited germline mutations and cancer.

General Oncology Mobile Apps: The Future of Cancer Care?

Mobile Apps: The Future of Cancer Care?

From anxiety and pain self-management to side effect monitoring in clinical trials, mobile applications are revolutionizing oncology. Researchers say the technology is even transforming clinical trials themselves.

General Oncology Spontaneous Regression of Cancer: Explanations and Predictions

Spontaneous Regression of Cancer: Explanations and Predictions

Clifford Pukel, MD, discusses from an immunological standpoint the mysterious phenomenon of spontaneous regression.

Breast Cancer Chemotherapy for HER2-negative Metastatic Breast Cancer

Chemotherapy for HER2-negative Metastatic Breast Cancer

The future of chemotherapy-based options for patients with HER2-negative MBC is evolving, with emerging agents and combinations being studied in ongoing clinical trials.

Breast Cancer Notch Inhibition: A Way Forward for Triple-negative Breast Cancer?

Notch Inhibition: A Way Forward for Triple-negative Breast Cancer?

Since the discovery of the notch pathway 25 years ago, several studies have found a link between different Notch receptors and specific forms of breast cancer, including triple-negative.

General Oncology Establishing Links Between Germline Mutations and Oncogenesis

Establishing Links Between Germline Mutations and Oncogenesis

In part 1 of a 2-part series, Bryant Furlow discusses advances in the understanding of inherited cancer syndromes and screening techniques for early tumor detection in high-risk patients.

General Oncology Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Effective Communication With Patients Is Critical for Improved Quality of Life, Lower Costs

Repeated active discussions with patients about distress, treatment options, and goals can both reduce costs and help to identify when aggressive treatment is no longer appropriate, according to hematologist/oncologist Stuart Goldberg, MD.

Breast Cancer CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps

CDK4/6 Inhibitors in Breast Cancer Treatment: Recent Research, Safety Profiles, Acquired Resistance, Next Steps

Breast tumors can become resistant to CDK 4/6 inhibitors, but improved understanding of the mechanisms of acquired resistance might point to additional treatment strategies.

Breast Cancer Q&A With Dr Chao: Oncotype DX Breast Recurrence Score® and Breast DCIS Score™

Q&A With Dr Chao: Oncotype DX Breast Recurrence Score® and Breast DCIS Score™

CTA spoke with Calvin Chao, MD, about how the Oncotype DX® test is implemented, how results can guide treatment, its use globally, and the future of prognostic testing.

General Oncology Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

Liquid Biopsies for Circulating Tumor Cells: A New Prognostic Tool?

While liquid biopsies could prove successful in monitoring treatments, these tests might also find early-stage cancers that, left alone, would never progress.

General Oncology Malware in Medicine: Prevention Is Key to Protection

Malware in Medicine: Prevention Is Key to Protection

The race against malware is much the same as a war between an infectious agent and a host: it's a battle between hackers and security experts — and it's not at all clear who is winning.

General Oncology Drug-herb and Drug-drug Interactions in Oncology

Drug-herb and Drug-drug Interactions in Oncology

Mixed data highlight the need for researchers to conduct studies to understand the clinical, rather than just theoretical, risks of HDIs and DDIs.

General Oncology Immune-mediated Hepatitis: Challenges in Management

Immune-mediated Hepatitis: Challenges in Management

The incidence of immune-mediated hepatitis in patients receiving immunotherapy varies based on the agent and other concomitant medications, though it is not uncommon.

Breast Cancer Q&A With Adam M. Brufsky, MD, PhD: Endocrine-based Therapy for HR-positive Metastatic Breast Cancer

Q&A With Adam M. Brufsky, MD, PhD: Endocrine-based Therapy for HR-positive Metastatic Breast Cancer

Cancer Therapy Advisor asked Dr Brufsky to comment on the evolving role of endocrine-based therapy for this patient population, including combinations based on molecular and genetic profiling.

General Oncology Can the FDA Curb Drug Prices for Cancer Treatment?

Can the FDA Curb Drug Prices for Cancer Treatment?

The US Food and Drug Administration announced a plan to hasten generic drug approvals and thereby increase competition, potentially reducing drug prices altogether.

General Oncology Industry Payments to Physicians: Confronting Conflicts of Interest

Industry Payments to Physicians: Confronting Conflicts of Interest

Though imperiled by efforts to repeal the Affordable Care Act, the federal Open Payments transparency program is helping to expose industry payments to physicians.

General Oncology Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Monoclonal Antibodies as Immunotherapy "Magic Bullets"

Many cancers in humans are weakly immunogenic — if immunogenic at all — and overcoming this inherent property of cancer cells will be critical for the future success of cancer immunology.

Prostate Cancer Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Megakaryocytes and Circulating Tumor Cells: Prognostic Value for Prostate Cancer

Circulating megakaryocytes are prognostic among patients with prostate cancer, bolstering evidence from breast cancer studies linking megakaryocytes to metastasis.

General Oncology Dermatomyositis and Cancer Risk

Dermatomyositis and Cancer Risk

Treating physicians should watch for any suspicious signs of cancer after DM is diagnosed.

Breast Cancer Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Q&A With Filippo Montemurro, MD: Considerations for Treatment With Trastuzumab Emtansine

Cancer Therapy Advisor asked Filippo Montemurro, MD, to place recent findings in context with respect to when T-DM1 might be best indicated.

Breast Cancer In Focus: Abemaciclib for Advanced Breast Cancer

In Focus: Abemaciclib for Advanced Breast Cancer

Several presentations demonstrated that abemaciclib provides clinical benefit for women with HR+/HER2-negative breast cancer who progress on or are resistant to endocrine therapy.

Breast Cancer Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

Overcoming Drug Resistance in the Treatment of Metastatic Breast Cancer

The management of metastatic breast cancer resistant or refractory to hormonal treatments, while still challenging, is rapidly improving.

Breast Cancer Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

Q&A With Narjust Duma, MD: Minority Patient Participation in Breast Cancer Clinical Trials

In this question-and-answer session, Cancer Therapy Advisor asked Dr Duma about her team's study and minority patient representation in breast cancer studies.

Breast Cancer Cryosurgery: The Future of Breast Cancer Treatment?

Cryosurgery: The Future of Breast Cancer Treatment?

Whether cryosurgery or cryoablation will prove a viable alternative to lumpectomy — the standard of care for women with early breast cancer — remains uncertain.

General Oncology Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers Look To Effectively Treat Patients With Cancer By Studying Exceptional Responders

Researchers are interested in identifying "exceptional responders" to cancer medications to help highlight biomarkers that will identify patients likely to respond to treatment.

General Oncology Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

Cancer Treatment Cost-effectiveness: Difficult To Define Due to Perception

If value is hard to define because it is perceived differently by different people, how can oncologists and policymakers accurately gauge cost-effectiveness?

Breast Cancer Breast Cancer Risk Higher in Men Previously Treated for Lymphoma According to Research

Breast Cancer Risk Higher in Men Previously Treated for Lymphoma According to Research

Researchers found that, among men previously treated for lymphoma, the incidence of breast cancer is higher than in the general population.

General Oncology Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians Advocate for Patients With Sexual Dysfunction After Cancer, A Quality of Life Issue

Clinicians are advocating that sexual dysfunction after cancer, which affects a large proportion of survivors, be addressed as a serious quality of life issue.

General Oncology Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

Pediatric Cancer Researchers Look To Preserve Reproductive Potential of Survivors

While survival rates of pediatric patients with cancer are greatly improved, researchers and clinicians are evaluating how to best preserve the reproductive potential of survivors.

Gynecologic Cancer Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

Ovarian/Breast Cancer Vaccine Research Looks To Establish Therapeutic Efficacy

Researchers are developing vaccines for patients with ovarian or breast cancer, with timing and vector being increasingly important factors for establishing therapeutic efficacy.

General Oncology Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

Q&A With Scott Roberts, PhD: Direct-to-Consumer Cancer Gene Testing

In this question-and-answer session, Cancer Therapy Advisor asked Dr Roberts about direct-to-consumer genomic testing for cancer risk.

General Oncology Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Bayesian Adaptive Randomization: A Q&A With Brian M. Alexander MD, PhD

Researchers developed a novel Bayesian adaptive randomization method that maximizes efficiency by focusing the algorithm to reduce uncertainty within patient-treatment baskets.

Breast Cancer The Role of Diet in Breast Cancer Incidence and Survival

The Role of Diet in Breast Cancer Incidence and Survival

More prospective studies are needed to determine the role of diet and the underlying mechanisms that explain dietary benefits among women with breast cancer.

General Oncology Random Mutations May Be Leading Cause of Oncogenesis

Random Mutations May Be Leading Cause of Oncogenesis

According to a study across all 32 cancer types, data suggest that 66% of mutations leading to cancer are the result of random events.

General Oncology Proposed US Budget Cuts: Effects on Cancer Research

Proposed US Budget Cuts: Effects on Cancer Research

According to the AACI, proposed budget cuts by the White House would likely mean a cut of close to $1 billion for the National Cancer Institute.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs